Serum immunoglobulin response and protection from homologous challenge by Proteus mirabilis in a mouse model of ascending urinary tract infection

Infection and Immunity

Volumn 67, Issue 12, 1999, Pages 6683-6687

  Johnson, David E ^a,b   Bahrani, Farah K ^b   Virginia Lockatell, C ^b   Drachenberg, Cinthia B ^b   Richard Hebel, J ^b   Belas, Robert ^c   Warren, John W ^b   Mobley, Harry L T ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIUM CULTURE; CATHETERIZATION; CYSTITIS; HYPOTHESIS; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULINS; KIDNEY; MICE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; URINARY TRACT INFECTIONS; VACCINATION;

EID: 0032752643     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bahrani, F. K., D. E. Johnson, D. Robbins, and H. L. T. Mobley. 1991. Proteus mirabilis flagella and MR/P fimbriae: isolation, purification, N-terminal analysis, and serum antibody response following experimental urinary tract infection. Infect. Immun. 59:3574-3580.
2. Bahrani, F. K., G. Massad, C. V. Lockatell, D. E. Johnson, R. G. Russell, J. W. Warren, and H. L. T. Mobley. 1994. Construction of an MR/P fimbrial mutant of Proteus mirabilis: role in virulence in a mouse model of ascending urinary tract infection. Infect. Immun. 62:3363-3371.
3. Bluestone, R., L. S. Goldberg, G. M. Kalmanson, and L. B. Guze. 1973. Systemic and urinary immune response in experimental E. coli pyelonephritis of mice. Int. Arch. Allergy 45:571-581.
4. Domingue, G., A. Sallhi, C. Roundtree, and W. Little. 1970. Prevention of experimental hematogenous and retrograde pyelonephritis by antibodies against enterobacterial common antigen. Infect. Immun. 2:175-182.
5. Eriksspm, S., J. Zbornik, H. Dahnsjo, P. Erlansoon, O. Kahlmeter, and C. A. Bauer. 1986. The combination of pivampicillin and pivmecillinam versus pivampicillin alone in the treatment of acute pyelonephritis. Scand. J. Infect. Dis. 18:431-438.
6. File, T., J. Tan, S.-J. Salstrom, and J. Johnson. 1985. Timentin versus piperacillin in the therapy of serious urinary tract infections. Am. J. Med. 79:91-95.
7. Gentry, L. O., B. A. Wood, M. D. Martin, and J. Smythe. 1980. Cefamandole alone and combined with gentamicin or tobramycin in the treatment of acute pyelonephritis. Scand. J. Infect. Dis. Suppl. 25:96-100.
8. Griffith, D. P., D. M. Musher, and C. Itin. 1976. Urease: the primary cause of infection-induced urinary stones. Invest. Urology 13:346-350.
9. Harlow, E., and D. Lane. 1988. Antibodies. A laboratory manual, p. 592-593. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
10. Johnson, D. E., C. V. Lockatell, R. Russell, J. R. Hebel, M. D. Island, A. Stapleton, W. E. Stamm, and J. W. Warren. 1998. Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice. Infect. Immun. 66:3059-3065.
11. Jones, B. D., C. V. Lockatell, D. E. Johnson, J. W. Warren, and H. L. T. Mobley. 1990. Construction of a urease-negative mutant of Proteus mirabilis: analysis of virulence in a mouse model of ascending urinary tract infection. Infect. Immun. 58:1120-1123.
12. Langermann, S., S. Palaszynski, M. Barnhart, G. Auguste, J. S. Pinkner, J. Burlein, P. Barren, S. Koenig, S. Leath, C. H. Jones, and S. J. Hultgren. 1997. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276:607-611.
13. Massad, G., C. V. Lockatell, D. E. Johnson, and H. L. T. Mobley. 1994. Proteus mirabilis fimbriae: construction of an isogenic pmfA mutant and analysis of virulence in a CBA mouse model of ascending urinary tract infection. Infect. Immun. 62:536-542.
14. Merrick, M. V., A. Notghi, N. Chalmers, A. G. Wilkinson, and W. S. Uttley. 1995. Long term follow up to determine the prognostic value of imaging after urinary tract infections. Part 2. scarring. Arch. Dis. Child. 72:393-396.
15. Moayeri, N., C. M. Collins, and P. O'Hanley. 1991. Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model. Infect. Immun. 59:3778-3786.
16. Mobley, H. L. T., R. Belas, V. Lockatell, G. Chippendale, A. L. Trifillis, D. E. Johnson, and J. W. Warren. 1996. Construction of a flagellum-negative mutant of Proteus mirabilis: effect on internalization by human renal epithelial cells and virulence in a mouse model of ascending urinary tract infection. Infect. Immun. 64:5332-5340.
17. Mobley, H. L. T., and G. R. Chippendale. 1990. Hemagglutinin, urease, and hemolysin production by Proteus mirabilis from clinical sources. J. Infect. Dis. 161:525-530.
18. Mobley, H. L. T., and R. P. Hausinger. 1989. Microbial ureases: significance, regulation, and molecular characterization. Microbiol. Rev. 53:85-108.
19. Mobley, H. L. T., and J. W. Warren. 1987. Urease-positive bacteriuria and obstruction of long-term catheters. J. Clin. Microbiol. 25:2216-2217.
20. Old, D., and R. Adegbola. 1982. Hemagglutinins and fimbriae of Morganella, Proteus, and Providencia. J. Med. Microbiol. 15:551-564.
21. Pazin, G. J., and A. I. Braude. 1974. Immobilizing antibodies in urine. II. Prevention of ascending spread of Proteus mirabilis. Investig. Urol. 12:129-133.
22. Pecha, B., D. Low, and P. O'Hanley. 1989. Gal-gal vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. J. Clin. Investig. 83:2102-2108.
23. Rubin, R. H., N. E. Tolkoff-Rubin, and R. S. Cotran. 1986. Urinary tract infection, pyelonephritis, and reflux nephropathy, p. 1085-1141. In B. M. Brenner and F. C. Rector (ed.), The kidney. The W. B. Saunders Co., Philadelphia, Pa.
24. Senior, B. W. 1979. The special affinity of particular types of Proteus mirabilis for the urinary tract. J. Med. Microbiol. 12:1-8.
25. Senior, B. W. 1983. Proteus morganii is less frequently associated with urinary tract infections than Proteus mirabilis - an explanation. J. Med. Microbiol. 16:317-322.
26. Stamey, T. A. 1987. Recurrent urinary tract infections in female patients: an overview of management and treatment. Rev. Infect. Dis. 9:S195-S208.
27. Stamm, W. E., M. McKevitt, P. L. Roberts, and N. J. White. 1991. Natural history of recurrent urinary tract infections in women. Rev. Infect. Dis. 13:77-84.
28. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.
29. Uehling, D. T., W. J. Hopkins, L. A. Dahmer, and B. Balish. 1994. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. J. Urol. 152:2308-2311.
30. Warren, J. W., K. H. Tenney, J. M. Hoopes, H. L. Muncie, and W. C. Anthony. 1982. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J. Infect. Dis. 146:719-723.